Comparing the efficacy and safety of IL-17 inhibitors for treatment of moderate-to-severe psoriasis: a randomized double blind pilot study with a review of literature

INTRODUCTION: Psoriasis is a chronic skin disease in which interleukin-17A (IL-17A) has been found to play an important role. Commercially available anti-IL-17 drugs include brodalumab, ixekizumab (IXE), and secukinumab (SEC). AIM: To compare the safety and efficacy of IXE and SEC in patients with m...

Descripción completa

Detalles Bibliográficos
Autores principales: AlMutairi, Nawaf, Eassa, Bayoumy Ibrahim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2020
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9880774/
https://www.ncbi.nlm.nih.gov/pubmed/36751540
http://dx.doi.org/10.5114/ada.2019.91496

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9880774/
https://www.ncbi.nlm.nih.gov/pubmed/36751540
http://dx.doi.org/10.5114/ada.2019.91496

Ejemplares similares